Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

BACKGROUND: Lutetium-177-DOTA-octreotate ((177)Lu-DOTATATE) significantly increases survival and response rates in patients with grade I and grade II neuroendocrine tumors (NETs). However, survival and response rates are significantly lower in patients with bulky liver metastases. Increasing the tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebbers, Sander C., Braat, Arthur J. A. T., Moelker, Adriaan, Stokkel, Marcel P. M., Lam, Marnix G. E. H., Barentsz, Maarten W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003409/
https://www.ncbi.nlm.nih.gov/pubmed/32024533
http://dx.doi.org/10.1186/s13063-019-3888-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003409/
https://www.ncbi.nlm.nih.gov/pubmed/32024533
http://dx.doi.org/10.1186/s13063-019-3888-0

Ejemplares similares